Annexon, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ANNX research report →
Companywww.annexonbio.com
Annexon, Inc. , a clinical-stage biopharmaceutical company, discovers and develops therapeutics for autoimmune, neurodegenerative, and ophthalmic disorders. The company's C1q is an initiating molecule of the classical complement pathway that targets distinct disease processes, such as antibody-mediated autoimmune disease and complement-mediated neurodegeneration.
- CEO
- Douglas E. Love
- IPO
- 2020
- Employees
- 106
- HQ
- Brisbane, CA, US
Price Chart
Valuation
- Market Cap
- $593.00M
- P/E
- -4.90
- P/S
- 0.00
- P/B
- 4.71
- EV/EBITDA
- -2.22
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -101.19%
- ROIC
- -89.17%
Growth & Income
- Revenue
- $0 · 0.00%
- Net Income
- $-206,690,000 · -49.56%
- EPS
- $-1.34 · -32.67%
- Op Income
- $-216,407,000
- FCF YoY
- -58.02%
Performance & Tape
- 52W High
- $7.18
- 52W Low
- $1.85
- 50D MA
- $5.69
- 200D MA
- $4.43
- Beta
- 1.22
- Avg Volume
- 2.59M
Get TickerSpark's AI analysis on ANNX
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Start Free Trial →Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| May 11, 26 | Carson William H. | buy | 8,000 |
| Apr 10, 26 | Carson William H. | buy | 8,000 |
| Mar 10, 26 | Carson William H. | buy | 8,000 |
| Mar 2, 26 | Dananberg Jamie | sell | 5,820 |
| Mar 2, 26 | Overdorf Michael | sell | 4,339 |
| Mar 2, 26 | Yednock Ted | sell | 5,566 |
| Mar 2, 26 | ARTIS DEAN RICHARD | sell | 5,894 |
| Mar 2, 26 | Lew Jennifer | sell | 5,565 |
| Feb 19, 26 | Love Douglas | other | 1,250,000 |
| Feb 19, 26 | Dananberg Jamie | other | 225,000 |
Our ANNX Coverage
We haven't published any research on ANNX yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate ANNX Report →